Australia Markets open in 3 hrs 33 mins

Soleno Therapeutics, Inc. (SLNO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.1840+0.0046 (+2.56%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.38
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 31.6700
52-week low 30.1300
50-day moving average 30.2171
200-day moving average 30.5320

Share statistics

Avg vol (3-month) 3844.2k
Avg vol (10-day) 3907.61k
Shares outstanding 579.81M
Implied shares outstanding 6N/A
Float 847.91M
% held by insiders 115.27%
% held by institutions 138.50%
Shares short (28 Apr 2022) 4283.44k
Short ratio (28 Apr 2022) 40.19
Short % of float (28 Apr 2022) 41.26%
Short % of shares outstanding (28 Apr 2022) 40.24%
Shares short (prior month 30 Mar 2022) 4601.42k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 305 Oct 2017
Ex-dividend date 4N/A
Last split factor 21:5
Last split date 305 Oct 2017

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Dec 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-40.11%
Return on equity (ttm)-97.60%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -30.3M
Net income avi to common (ttm)-30.91M
Diluted EPS (ttm)-0.3880
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)21.3M
Total cash per share (mrq)0.27
Total debt (mrq)457k
Total debt/equity (mrq)2.57
Current ratio (mrq)2.80
Book value per share (mrq)0.25

Cash flow statement

Operating cash flow (ttm)-27.77M
Levered free cash flow (ttm)-15.79M